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IMPORTANCE Type 2 diabetes (T2D) is increasingly common in young individuals. Primary
prevention and screening among children and adolescents who are at substantial risk for T2D
are recommended, but implementation of T2D screening practices in the pediatric primary
care setting is uncommon.
OBJECTIVE To determine the feasibility and effectiveness of a computerized clinical decision
support system to identify pediatric patients at high risk for T2D and to coordinate screening
for and diagnosis of prediabetes and T2D.
DESIGN, SETTING, AND PARTICIPANTS This cluster-randomized clinical trial included patients
from 4 primary care pediatric clinics. Two clinics were randomized to the computerized
clinical decision support intervention, aimed at physicians, and 2 were randomized to the
control condition. Patients of interest included children, adolescents, and young adults 10
years or older. Data were collected from January 1, 2013, through December 1, 2016.
INTERVENTIONS Comparison of physician screening and follow-up practices after adding a
T2Dmodule to an existing computer decision support system.
MAIN OUTCOMES ANDMEASURES Electronicmedical record (EMR) data from patients 10
years or older were reviewed to determine the rates at which pediatric patients were
identified as having a bodymass index (BMI) at or above the 85th percentile and 2 or more
risk factors for T2D and underwent screening for T2D.
RESULTS Medical records were reviewed for 1369 eligible children (712 boys [52.0%] and 657
girls [48.0%]; median [interquartile range] age, 12.9 [11.2-15.3]), of whom 684were
randomized to the control group and 685 to the intervention group. Of these, 663 (48.4%)
had a BMI at or above the 85th percentile. Five hundred sixty-five patients (41.3%)met T2D
screening criteria, with no difference between control and intervention sites. The T2D
module led to a significant increase in the percentage of patients undergoing screening for
T2D (89 of 283 [31.4%] vs 26 of 282 [9.2%]; adjusted odds ratio, 4.6; 95% CI, 1.5-14.7) and a
greater proportion attending a scheduled follow-up appointment (45 of 153 [29.4%] vs 38 of
201 [18.9%]; adjusted odds ratio, 1.8; 95% CI, 1.5-2.2).
CONCLUSIONS AND RELEVANCE Use of a computerized clinical decision support system to
automate the identification and screening of pediatric patients at high risk for T2D can help
overcome barriers to the screening process. The support system significantly increased
screening among patients whomet the American Diabetes Association criteria and adherence
to follow-up appointments with primary care clinicians.
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T he American Diabetes Association (ADA) recommendsscreening among children, adolescents, and youngadults 10 years or older (hereinafter referred to as
youths)whoareat risk for type2diabetes (T2D).1 TheADAalso
recommendsprimarypreventionefforts, suchas lifestylemodi-
fication, be directed to individuals whose glucose levels are
elevated but not diagnostic of diabetes (ie, prediabetes).2
Although consensus exists regarding screening for T2D in
youths at high risk for disease, implementation in the pri-
mary care setting is not ideal.3,4 Barriers to screening include
physician time constraints, lack of knowledge about screen-
ing and management guidelines, lack of educational tools to
help communicate with patients and families, and failure to
complete testing and attend follow-up appointments.3,4
We implemented theADAscreening guidelines for T2Dat
pediatric primary care practices by using a computer deci-
sionsupport systemdevelopedbyour researchgroup: theChild
Health ImprovementThroughComputerAutomation (CHICA)
system.5 The application of a computer decision support sys-
tem to the screening and diagnosis of T2D in youths is rela-
tively unexplored.3 We hypothesized that the system could
help overcome the barriers to screening for prediabetes and
T2D described by pediatricians. Our objective was to deter-
mine the feasibility and effectiveness of the CHICA system in
identifying at-risk youths and coordinating the screening for
and diagnosis of prediabetes and T2D via a randomized clini-
cal trial.
Methods
This study was performed in 4 primary care practices in the
Eskenazi Health Center Primary Care system from January
1, 2013, through December 1, 2016. The trial protocol (avail-
able in the Supplement) was approved by the institutional
review board of Indiana University. A waiver of consent was
obtained from the institutional review board because
(1) little risk accrued in supplying physicians with guide-
lines; (2) study procedures were within the standards of
care; (3) informing families that they may be part of a study
could bias their response to screening questions; and
(4) obtaining informed consent from every patient was
impracticable and presented a higher risk for loss of patient
confidentiality.
Participants
Our interventionwas aimed at physicians. However, the out-
comes of interest are patient based. The patients in this study
were 10years or older andwere automatically cluster random-
ized to the control or the intervention group based on which
of the 4 clinics they attended. No patients were contacted by
researchers, their physician, or other staff regarding the study.
TheADA recommends that youths be screened for T2D if they
have a body mass index (BMI) (calculated as weight in kilo-
gramsdividedbyheight inmeters squared)atorabove the85th
percentile for age and sex and 2 or more additional risk fac-
tors startingat 10yearsof ageor at theonsetofpuberty,which-
ever occurs first.1
Study Design
Weconducted a cluster-randomized clinical trial inwhichwe
compared screening for T2D among youth meeting ADA cri-
teriabetween the interventionandcontrol practices (Figure 1).
Four clinics were enrolled by randomizing the 2 largest clin-
ics to the intervention and control conditions by a coin toss.
Two additional clinics were alternately assigned to the inter-
vention and control conditions such that study populations
Figure 1. CONSORTDiagram
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intervention
0 Did not receive allocated
intervention
283 Included in analysis for
end point
0 Excluded from analysis
282 Included in analysis for
end point
0 Excluded from analysis
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0 Lost to follow-up
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1423 Electronic medical records
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+ ≥2 risk factors for T2D
282 BMI ≥85th percentile
+ ≥2 risk factors for T2D
1369 Randomized
The final analysis included 565 patients with risk factors for type 2 diabetes
(T2D). BMI indicates bodymass index.
Key Points
Question Can use of a computerized clinical decision support
system help decrease barriers to screening for and diagnosis of
prediabetes and type 2 diabetes in pediatric patients?
Findings In this cluster-randomized clinical trial performed in 4
pediatric clinics that included 1369 patients, computerized clinical
decision support significantly increased the rates of screening for
prediabetes and type 2 diabetes among pediatric patients meeting
the risk criteria compared with patients in a control group of
clinics.
Meaning Use of a computerized clinical decision support system
can help overcome barriers and significantly increase the rates of
screening and clinical follow-up for prediabetes and type 2
diabetes in pediatric patients.
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would be similar in size. Intervention clinics used the system
that incorporated theCHICAT2Dmodule,which includedT2D
guidelines. Control clinics used the traditional CHICA system
thatdidnot includeT2Dguidelines.Seventeenphysiciansprac-
ticed at the intervention sites and 12 practiced at the control
sites.Although randomizationat thephysicianorpatient level
mayhavebeen sample-size efficient,we randomizedby clinic
because contamination was a concern. If we randomized by
physician, thestudywouldbecomplicatedwhenpatientswere
seen bydifferent physicians in andout of the study. Ifwe ran-
domizedbypatient, theon-and-offuseof theCHICAT2Dmod-
ulewould complicate physicianwork flow.6 Both randomiza-
tion methods could lead to contamination.
CHICA System
TheCHICAsystemhasbeendescribed indetail previously.5,7-10
CHICA is a computerdecision support systemcoupledwith an
electronicmedical record (EMR) forpediatricprimarycareand
chronic diseasemanagement. CHICAuses a prescreener form
containing 20 questions for parents. Questions are based on
national guidelines, and selection is determined by applying
logic rules to data contained in the individual’s EMR.7 A phy-
sician worksheet contains as many as 6 prompts that include
check box responses for the physician’s assessment and ac-
tions. The prescreener questions and physician prompts are
programmatically chosen by the patient’s age and EMR data.
TheCHICAT2Dmodule prescreener included informationon
family history, race or ethnicity, andmaternal gestational dia-
betes, andphysicianprompts includeddocumenting signsand
conditions associated with insulin resistance. The EMR con-
tained diagnostic codes, orders, prescriptions, and laboratory
data from the statewide health information exchange, the In-
dianaNetwork for Patient Care.11 CHICAwas implemented on
tablets for the prescreener form, and the physicianworksheet
switched from a paper to an online format during the study.
Intervention: The CHICA T2DModule
Theoutline for theCHICAT2Dmodule is provided inFigure 2
and Figure 3. The BMI data were analyzed by the CHICA sys-
tem; when the BMI was at or above the 85th percentile, a
prompt on the physician worksheet asked whether the pa-
tient had any symptoms or conditions associated with insu-
lin resistance. This information was analyzed along with the
data from the prescreener form to determinewhether the pa-
tient had 2 or more risk factors for T2D. If at least 2 risk fac-
tors were present, the physicianwas prompted to ordermea-
surement of fasting plasma glucose (FPG) and hemoglobin
(HbA1c) levels. Measurements of both FPG and HbA1C levels
were included because whether similar FPG and HbA1C cut-
off points are appropriate for the pediatric and adult popula-
tions remainsunclear, andcontroversyexists overwhich is the
most appropriate screening test inpediatrics.4,12,13 Paper edu-
cational materials regarding the importance of screening for
T2D and instructions for the blood test were printed and pro-
vided to families. The CHICA T2D module generated auto-
mated telephone calls about laboratory testing (with instruc-
tions for fasting) and follow-up appointments. Reminder
telephone calls were unique to the CHICA T2Dmodule.
If the FPG level was greater than 125 mg/dL (to convert to
millimoles per liter, multiply by 0.0555) or the HbA1C level
was at least 6.5% (diabetes range; to convert to a proportion of
total hemoglobin, multiply by 0.01), a prompt instructed the
Figure 2. Screening in Pediatrician’s OfficeWith Child Health Improvement Through Computer Automation
(CHICA) Type 2 Diabetes (T2D)Module
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physician to refer the patient to pediatric endocrinology for
further evaluation and/or treatment; a referral page was gen-
erated if thephysician respondedyes to theprompt. If screen-
ing resultswere at or near the prediabetes range (ie, FPG level
of95-125mg/dLandHbA1c level<6.5%orFPG level≤125mg/dL
andHbA1c level of 5.7%-6.4%), apromptwasgenerated for the
physician to order an oral glucose tolerance test (OGTT) and
follow-up appointment. The rationale for the OGTT at these
FPG andHbA1c cut points was that the reference standard for
thediagnosis of prediabetes andT2D inyouth isunknownand
additional information on glucose tolerance would be help-
ful indetermining riskand treatment.14Weused95 rather than
100 mg/dL as the cut point for FPG level because this popu-
lation was at high risk for T2D, and the FPG level is often not
elevated in prediabetes and early T2D, when hyperglycemia
occurs only in the postprandial state.15 If the OGTT result in-
dicated diabetes (OGTT result, >199 mg/dL), a prompt in-
structed the physician to refer the patient to pediatric endo-
crinology, and a referralwas faxed if the physician responded
yes to the prompt.
Figure 3. Diagnosis andManagement of Type 2 Diabetes (T2D) RiskWith Child Health Improvement
Through Computer Automation (CHICA) T2DModule
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For screening test results consistentwithprediabetes, the
pediatrician was prompted to order a 6-month follow-up ap-
pointment. If an appointmentwas scheduled, theCHICAT2D
module generated a reminder telephone call about this ap-
pointment. During follow-up appointments, the pediatrician
was prompted to provide the patient and the patient’s parent
orguardianwithnutritionandexercise recommendations, and
paper educational handouts related to these topicswere gen-
erated. Ifpatientsdidnotattendfollow-upappointments, these
handouts were not provided.
Main Outcomes
The primary outcome was the percentage of youths identi-
fied with documented risk factors for T2D. We hypothesized
that the use of the prescreener formwould result in the iden-
tification of more risk factors and therefore identify more
youths at risk. To determine which youths were truly at risk
(regardlessofphysician identification), datawere collectedvia
EMR abstraction and review of CHICA data for the interven-
tion and control clinics. A random sample of 350 EMRs of
youths 10 years or older per clinic was used for a total of 700
per study arm. Research assistants were trained to review
the EMR for information related to screening and diagnosis
of T2D. In the case of multiple visits by the same patient dur-
ing the study period, the EMR was eligible for review once.
The secondary outcome was the percentage of youths who
had laboratory tests ordered and completed (screening).
Whether a patient underwent screening for T2D was identi-
fied as yes when an FPG or an HbA1c level or both were docu-
mented in the EMR.
Sample Size and Power Estimation
We estimated the real screening rate to be approximately
10% in our clinics under standard practice. Based on a litera-
ture review, we expected that more than 20% of the youths
10 years or older would have a BMI at or above the 85th per-
centile and at least 2 risk factors for T2D.16,17 We would have
80% power to detect a 10% difference in the proportion of
children who would undergo screening for T2D between the
intervention and control groups with a total effective sample
size of 438 patients. Because the randomization was at the
clinic level, responses from patients in the same clinic were
likely correlated, causing a decrease in analytical power. The
magnitude of power reduction depends on the level of
heterogeneity of the clinical sites; such heterogeneity is
often characterized by the intraclinic correlation. Although
we did not anticipate significant variability in the 4 clinics,
we assumed intraclinic correlation of no more than 0.006.
Using this conservative estimate, we needed to review the
EMRs of 317 children per clinic. To accommodate a 10% rate
of missing BMI data, we increased the sample size to 350 per
clinic.
Statistical Analysis
Baseline characteristics of the participants were compared
using the χ2 test or the Fisher exact test for categorical out-
comesand theWilcoxon rank sumtest for agebecause thedis-
tribution was skewed. Logistic regression models estimated
associationsbetween the interventionand theoddsof screen-
ing. Clinic-level random intercepts accommodated thepoten-
tial dependence of responses from in the same clinic. We did
not expect correlationdue to clusteringof participants in clin-
ics. Covariates (age, sex, race, and insurance) were screened
for inclusion by testing whether the groups showed a differ-
ence at P < .10. Group differences in primary and secondary
outcomeswereadjusted for age, sex, race, and insurancewhen
a covariate was significant at P < .10. Analyses were per-
formed using SAS software (version 9.4; SAS Institute Inc).
Results
This study included 1423 EMRs abstracted for eligibility. To
assess the reliability of EMR abstraction, a random sample of
20% of the records was abstracted twice. The interrater reli-
ability was 93%, and the κ statistic was 0.87. Of these, 54
(3.8%) were missing BMI data and were excluded, leaving
1369 for analysis (712 boys [52.0%] and 657 girls [48.0%];
median [interquartile range] age, 12.9 [11.2-15.3]). Of these,
663 patients (48.4%) had a BMI at or above the 85th percen-
tile. Demographic characteristics of the eligible patients are
shown in Table 1. Differences between the control and inter-
vention groups were found for age (median [interquartile
range] age, 12.6 [11.3-14.5] vs 13.4 [11.2-15.8] years), race, and
insurance. Control clinics had a greater proportion of His-
panic patients (243 [35.5%] vs 192 [28.1%]), and intervention
clinics had a greater proportion of black patients (336
[49.1%] vs 376 [55.1%]) (Table 1). Intervention clinics had
more insurance marked as self-pay, other, or none (51 [7.8%]
vs 99 [15.2%]). When demographic characteristics of the
subgroup who met the criteria for screening for T2D were
compared, we found no difference in age or insurance
between control and intervention clinics, whereas the race
difference (black, 135 [47.9%] vs 150 [53.0%]; Hispanic, 126
[44.7%] vs 99 [35.0%]) remained (Table 1).
The proportion of youths meeting BMI criteria and hav-
ing at least 2 other risk factors forT2Dwas565of 1369 (41.3%).
This proportiondidnot differ between control (282of 684pa-
tients [41.2%]) and intervention (283of685 [41.3%]) sites. This
findingwasourprimaryoutcome,andtherefore theCHICAT2D
module did not increase the proportion who had docu-
mented risk factors for T2D.
Onehundred thirty-twopatientsunderwent screening for
T2D, resulting in a screening rate for the entire study popula-
tion of 9.6%. The adjusted odds ratio of screening in the in-
terventiongroupwas3.7 (95%CI, 1.8-7.7) (Table2). Among the
565 youths meeting criteria, physicians ordered any screen-
ing test for T2D for 115 (20.4%). The adjustedodds ratio for the
intervention group was 4.6 (95% CI, 1.5-14.7) compared with
the control group (Table 2).
Wefounda lowrateoforderingFPGfor screening (Table2).
Noneof thedocumentedFPGlevelswasgreater than125mg/dL
(diabetes range).Oneof 3 control patients (33.3%)whounder-
wentFPGscreeninghadanFPG level in theprediabetes range,
and 2 of 9 intervention patients (22.2%)who underwent FPG
screening had FPG levels in the prediabetes range.
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The rate of orderingHbA1c assessment among thosemeet-
ing ADA criteria was higher than that for FPG assessment
(Table 2). Ninety-eight of 565 eligible youths (17.3%) under-
wentHbA1c screening.Oneof thedocumentedHbA1c levelswas
at least 6.5% (diabetes range) in the interventiongroup.Of the
controlpatientsundergoingscreening, 5 (31.2%)hadHbA1c lev-
els ranging from 5.7% to less than 6.5% (prediabetes range),
and 13 of 63 interventionpatients (20.6%)undergoing screen-
inghadHbA1c levels in theprediabetes range.Nopatientswere
scheduled for OGTT.
The proportion of youths who were scheduled for a fol-
low-upappointmentwith theirpediatrician is showninTable2.
The proportions of youths who actually attended a sched-
uled follow-up appointment were 38 of 201 control patients
(18.9%) and 45 of 153 intervention patients (29.4%). One pa-
tient was referred to pediatric endocrinology.
Discussion
The CHICA T2D module more than quadrupled the rates of
screening for T2D among youths with a BMI at or above the
85th percentile and 2 or more risk factors at well-care visits,
as recommendedby theADAguidelines.TheCHICAT2Dmod-
ule was also associated with greater attendance at follow-up
appointments. The intervention did not lead to more pa-
tients beingdiagnosedwithprediabetes or T2D, but our study
was not powered to detect changes in clinical outcomes. The
CHICA system is unique because it permits us to insert guide-
line-based care into existing clinic practices in a format that
integrates easily into routine pediatric care. The CHICA T2D
module can therefore overcome many barriers to the T2D
screening process.
Table 1. Demographic Characteristics of the Study Population
Characteristic
Randomized Group,
No. (%)
Criteria-Eligible Randomized Group,
No. (%)a
Control
(n = 684)
Intervention
(n = 685)
Control
(n = 282)
Intervention
(n = 283)
Age, median (IQR), y 12.6 (11.3-14.5) 13.4 (11.2-15.8) 12.6 (11.3-14.5) 13.1 (11.1-15.7)
Sex
Male 371 (54.2) 341 (49.8) 138 (48.9) 130 (45.9)
Female 313 (45.8) 344 (50.2) 144 (51.1) 153 (54.1)
Raceb
Black 336 (49.1) 376 (55.1) 135 (47.9) 150 (53.0)
Hispanic 243 (35.5) 192 (28.1) 126 (44.7) 99 (35.0)
White 59 (8.6) 55 (8.1) 12 (4.3) 13 (4.6)
Other/unknown 46 (6.7) 60 (8.8) 9 (3.2) 21 (7.4)
Insurancec
Commercial 42 (6.4) 35 (5.4) 17 (6.3) 13 (4.8)
Medicaid 560 (85.8) 519 (79.5) 227 (84.1) 222 (82.2)
Self-pay 25 (3.8) 36 (5.5) 12 (4.4) 15 (5.6)
Other 25 (3.8) 53 (8.1) 14 (5.2) 17 (6.3)
None 1 (0.2) 10 (1.5) 0 3 (1.1)
Abbreviation: IQR, interquartile
range.
a Includes 565 patients whomet
criteria of a bodymass index at or
above the 85th percentile and 2 or
more other risk factors.
bData were missing for 2 patients in
the randomized intervention group.
c Data were missing for 31 patients in
the randomized control group,
32 patients in the randomized
intervention group, 12 patients in
the criteria-eligible randomized
control group, and 13 patients in the
criteria-eligible randomized
intervention group.
Table 2. Adjusted ORs of Screening and Follow-up Tests for Intervention vs Control Groups
Outcome
Randomization Group, No./Total No. (%)
Unadjusted
OR
Adjusted OR
(95% CI)Control Intervention
T2D screening rate
Entire study population 33/684 (4.8) 99/685 (14.4) 3.3 3.7 (1.8-7.7)a
Study population with ≥2 risk
factors
26/282 (9.2) 89/283 (31.4) 4.5 4.6 (1.5-14.7)b
FPG test
Ordered 13/282 (4.6) 12/283 (4.2) 0.9 1.1 (0.5-2.7)b
Result documented 3/13 (23.1) 9/12 (75.0) 10.0 10.0 (1.7-57.8c
HbA1c test
Ordered 25/282 (8.9) 73/283 (25.8) 3.6 3.7 (1.5-9.3)b
Result documented 16/25 (64.0) 63/72 (87.5) 3.9 3.9 (0.6-24.3)c
Result in prediabetes range 5/16 (31.2) 13/63 (20.6) 0.6 0.6 (0.3-1.1)c
Follow-up
Scheduled 201/282 (71.3) 153/283 (54.1) 0.5 0.5 (0.2-1.3)b
Attended 38/201 (18.9) 45/153 (29.4) 1.8 1.8 (1.5-2.2)c
Abbreviations: FPG, fasting plasma
glucose; HbA1c, hemoglobin A1c;
OR, odds ratio; T2D, type 2 diabetes.
a Adjusted for age, sex, race, and
insurance.
bAdjusted for race.
c Not adjusted owing to small sample
size.
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Addingtelephonereminders to theCHICAT2Dmodulewas
associatedwith a greater likelihoodof attending follow-upap-
pointments. These automated patient reminders are likely to
improve service delivery and to provide benefit to patients.18
Computer decision support systems have been shown to im-
prove adherence to practice recommendations in pediatric
primary care and hospital settings.9,19-22 However, such sys-
tems are only beginning to be implemented for patient-
centered medicine based on information available in the
EMR.10 Screening for T2D in youths has not been studied be-
foreusing this technology.Our findingsnot onlyhighlight the
potential effect of computer decision support for pediatri-
cians caring for populations at high risk for T2D but also set
the stage for introducing these systems in other EMRs and for
other chronic conditions.
This populationwas enrichedwith youthofminority race
or ethnicity with a high rate of overweight and obesity (BMI
≥85th percentile). In comparison, the 2011 to 2012 National
Health and Nutrition Examination Survey data for non-
Hispanicblackyouths showed that 38.1%aged6 to 11years and
39.8% aged 12 to 19 years had a BMI at or above the 85th per-
centile; data forHispanic youths showed that 46.2%aged6 to
11 years and 38.1% aged 12 to 19 years had a BMI at or above
the 85th percentile.23 The proportion of youths meeting BMI
criteria and having at least 2 other risk factors for T2D in our
studywas 41.3%.However, fewer thanhalf of the youthswho
met this criterion had laboratory tests performed. Even with
our intervention, only 73 (25.8%) of 283 youths known to be
at risk for T2Dhad orders formeasurement of HbA1c level. Al-
though significantly improved compared with the control
group, this rate is still quite low.Ratesofprediabetes (5 [31.2%]
of 16 control patients and 13 [20.6%] of 63 intervention pa-
tients) and T2D (0 of 16 control patients and 1 [1.6%] of 63 in-
tervention patients) in youths undergoing screening in this
study were similar to those of previous reports in similar
populations.24,25 Thus, if a larger proportion had undergone
screening, more individuals likely would have received a di-
agnosis andbeenscheduled for follow-up.Lowratesof screen-
ingmay reflect the lackof effective treatmentmethods and re-
sources for T2D prevention in pediatrics. Comprehensive,
family-inclusive behavior modification programs are lim-
ited,but someevidenceofbenefit exists.26However, suchpro-
grams arenotwidely available, not coveredby insurance, and
often not accessible by the target population.27,28
Physiciansopted tousemeasurementofHbA1c level as the
preferred screening test. Use of this test reflects convenience
and increasing recognitionofpublishedclinical guidelines en-
dorsing HbA1c level measurement as an appropriate screen-
ing test.4,13,29Measurement of HbA1c level has low sensitivity
andspecificitywhencomparedwithOGTTfordiagnosingT2D;
but as we observed, OGTT is not used in clinical practice.30,31
LevelsofHbA1c andFPGreflect important, butdifferent,physi-
ologic aspects of glucose homeostasis. The FPG level is often
not elevated in earlyT2D,whereashyperglycemiaoccurs only
in thepostprandial state.15 In addition, theHbA1c level ismore
persistent over time.31 Based on ease and acceptability, HbA1c
testing is preferred, although research is necessary to deter-
mineoptimal screeningstrategies foryouthpopulationsathigh
risk for T2D.
Limitations
This study has limitations that warrant consideration. Al-
thoughwe conducted a large randomized clinical trial, only 4
clinics were involved. We cannot ensure that no differences
between the control and intervention groups existed in BMI
distribution, although all patients in this study had BMI at or
above the 85th percentile or no differences in other coexist-
ing conditions. We also could not determine correlation due
to clustering of patients in clinics. The age distribution of the
patients was skewed toward younger adolescents because
manypatientsolder than 15yearswere seen ina separate clinic
that didnot useCHICA. This separationmayhave led to lower
rates of prediabetes and T2D detected by screening proce-
dures. The CHICA system is also currently used only in Eske-
nazi Health and Indiana University Health primary care set-
tings. We are working to provide CHICA as a web service that
can interface with commercial EMR systems. For dissemina-
tion, current ADA recommendations, which treat OGTT re-
sults and FPG and HbA1c levels as equivalent and do not rec-
ommend sequential testing in asymptomatic individuals,
should be used.32 The FPG cut point of 100 mg/dL should be
used instead of 95 mg/dL, as was used in this study.
Conclusions
Use of a computerized clinical decision support system to au-
tomate the identificationand screening forT2Dcanhelpover-
come barriers to the screening process. The system signifi-
cantly increased ratesof screeningamongyouthswhomet the
ADA criteria and adherence to follow-up appointments with
primary care clinicians. Whether the system can help im-
prove health outcomes in youth diagnosed with prediabetes
or T2D remains to be determined.
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